Limitation of myocardial reperfusion injury by AMP579, an adenosine A(1)/A(2A) receptor agonist: Role of A(2A) receptor and Erk1/2.
CARDIOVASC DRUG THER
415 - 425.
AMP579, an adenosine A(1)/A(2A) receptor agonist, protects against myocardial infarction when given at the onset of reperfusion. However, it is unclear which receptor subtype mediates its protective actions. Anaesthetised rabbits were subjected to 30 min regional ischaemia/180 min reperfusion in vivo. AMP579 (30 mug kg(-1) bolus + 3 mug kg(-1) min(-1) for 70 min) reduced heart rate and mean arterial blood pressure with the latter being abolished with ZM241385 ( a selective A(2A) receptor antagonist). AMP579 reduced infarct size from 46.0 +/- 3.4% in vehicle control hearts to 29.6 +/- 3.5% ( P < 0.05), an effect that was attenuated in the presence of ZM241385, in a dose-dependent manner (38.2 +/- 4.9% at 1 mg kg(-1); 45.1 +/- 4.2% at 2.5 mg kg(-1)). CGS21680 (a selective A(2A) agonist, 30 mu g kg(-1) bolus + 3 mu g kg(-1) min(-1) for 70 min), or CCPA ( a selective A(1) agonist, 50 mu g kg(-1)), alone or in combination showed no protection (44.7 +/- 5.8%; 39.8 +/- 2.8%; 39.1 +/- 5.1%, respectively) when given at the commencement of reperfusion. Furthermore, we hypothesized that the prosurvival MEK1/2-Erk1/2 pathway was involved in the downstream mechanism of cardioprotection afforded by AMP579. PD098059, an inhibitor of MEK1/2 showed a dose dependent attenuation on infarct size (39.9 +/- 5.3% at 2 mg kg(-1); 48.3 +/- 5.7% at 4 mg kg(-1), iv, respectively). PD098059 alone had no effect on infarct size (44.7 +/- 5.8%, 2 mg kg(-1), iv). We conclude that AMP579 limits myocardial infarction by activating A2A adenosine receptors that might be linked to further downstream kinases such as Erk1/2.
|Title:||Limitation of myocardial reperfusion injury by AMP579, an adenosine A(1)/A(2A) receptor agonist: Role of A(2A) receptor and Erk1/2|
|Keywords:||adenosine, AMP579, adenosine A(1) and A(2A) receptors, infarct size, ischaemia-reperfusion, myocardial infarction, reperfusion injury, prosurvival pathways, Erk1/2, ATP-CHANNEL ACTIVATION, INFARCT SIZE, RABBIT HEART, INTRACORONARY ADENOSINE, INTRAVENOUS ADENOSINE, SELECTIVE ACTIVATION, A(3) RECEPTORS, P42/P44 MAPK, PROTECTION, ISCHEMIA|
|UCL classification:||UCL > School of Life and Medical Sciences
UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science
UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Hatter Cardiovascular Institute
Archive Staff Only